CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Total	Stockholders’ Equity	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Treasury stock, at cost	Non-controlling interest
Balance at Dec. 31, 2023	$ 80,096	$ 78,734	$ 12	$ 837,416	$ (760,227)	$ 2,198	$ (665)	$ 1,362
Balance (in Shares) at Dec. 31, 2023			111,132,222
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs (in shares)			1,226,498
Issuance of RSAs  (in shares)			38,130
Exercise of common stock options	544	544		544
Exercise of common stock options (in Shares)			186,074
Reclassification of warrant liability to common stock warrants	2,468	2,468		2,468
Stock-based compensation expense	6,293	6,293		6,293
Net loss	(31,610)	(31,610)			(31,610)
Foreign currency translation adjustment	(522)	(522)				(522)
Balance at Mar. 31, 2024	57,269	55,907	$ 12	846,721	(791,837)	1,676	(665)	1,362
Balance (in Shares) at Mar. 31, 2024			112,582,924
Balance at Dec. 31, 2023	80,096	78,734	$ 12	837,416	(760,227)	2,198	(665)	1,362
Balance (in Shares) at Dec. 31, 2023			111,132,222
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(69,609)
Foreign currency translation adjustment	304
Balance at Sep. 30, 2024	65,571	65,571	$ 14	893,584	(829,836)	2,502	(693)
Balance (in Shares) at Sep. 30, 2024			127,545,321
Balance at Mar. 31, 2024	57,269	55,907	$ 12	846,721	(791,837)	1,676	(665)	1,362
Balance (in Shares) at Mar. 31, 2024			112,582,924
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs	1	1	$ 1
Vesting of RSUs (in shares)			294,589
Issuance of RSAs  (in shares)			231,323
Exercise of common stock options	1,106	1,106		1,106
Exercise of common stock options (in Shares)			438,118
Exercise of common warrants	21,036	21,036	$ 1	21,035
Exercise of common warrants (in shares)			9,738,930
Reclassification of warrant liability to common stock warrants	4,308	4,308		4,308
Stock-based compensation expense	2,792	2,792		2,792
Interest payment through issuance of shares of Common Stock	1,867	1,867		1,867
Interest payment through issuance of shares of Common Stock (in Shares)			237,722
Redemption of non-controlling interests	67	1,429		1,429				(1,362)
Redemption of non-controlling interests (in Shares)			397,037
Shares of Common Stock received from settlement of employee receivables	(28)	(28)					(28)
Shares of Common Stock received from settlement of employee receivables (in Shares)			(3,016)
Net loss	(24,390)	(24,390)			(24,390)
Foreign currency translation adjustment	(179)	(179)				(179)
Balance at Jun. 30, 2024	63,849	63,849	$ 14	879,258	(816,227)	1,497	(693)
Balance (in Shares) at Jun. 30, 2024			123,917,627
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs (in shares)			243,481
Exercise of common stock options	232	232		232
Exercise of common stock options (in Shares)			207,977
Exercise of common warrants	6,860	6,860		6,860
Exercise of common warrants (in shares)			3,176,236
Reclassification of warrant liability to common stock warrants	4,747	4,747		4,747
Stock-based compensation expense	2,487	2,487		2,487
Net loss	(13,609)	(13,609)			(13,609)
Foreign currency translation adjustment	1,005	1,005				1,005
Balance at Sep. 30, 2024	65,571	$ 65,571	$ 14	893,584	(829,836)	2,502	(693)
Balance (in Shares) at Sep. 30, 2024			127,545,321
Balance at Dec. 31, 2024	50,121		$ 14	912,241	(862,106)	665	(693)
Balance (in Shares) at Dec. 31, 2024			131,136,712
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs (in shares)			828,282
Exercise of common stock options	232			232
Exercise of common stock options (in Shares)			77,515
Exercise of common warrants	517			517
Exercise of common warrants (in shares)			239,201
Reclassification of warrant liability to common stock warrants	1,241			1,241
Stock-based compensation expense	6,283			6,283
Issuance of common warrants	5,766			5,766
Net loss	(58,579)				(58,579)
Foreign currency translation adjustment	992					992
Balance at Mar. 31, 2025	6,573		$ 14	926,280	(920,685)	1,657	(693)
Balance (in Shares) at Mar. 31, 2025			132,281,710
Balance at Dec. 31, 2024	50,121		$ 14	912,241	(862,106)	665	(693)
Balance (in Shares) at Dec. 31, 2024			131,136,712
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(121,291)
Foreign currency translation adjustment	3,076
Balance at Sep. 30, 2025	(22,118)		$ 15	958,216	(983,397)	3,741	(693)
Balance (in Shares) at Sep. 30, 2025			134,727,753
Balance at Mar. 31, 2025	6,573		$ 14	926,280	(920,685)	1,657	(693)
Balance (in Shares) at Mar. 31, 2025			132,281,710
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs	1		$ 1
Vesting of RSUs (in shares)			361,918
Issuance of RSAs  (in shares)			120,265
Exercise of common stock options	1,190			1,190
Exercise of common stock options (in Shares)			220,687
Exercise of common warrants	65			65
Exercise of common warrants (in shares)			30,093
Stock-based compensation expense	2,762			2,762
Change in estimate of issuance of 2028 common warrants	3,240			3,240
Net loss	(63,195)				(63,195)
Foreign currency translation adjustment	2,149					2,149
Balance at Jun. 30, 2025	(47,215)		$ 15	933,537	(983,880)	3,806	(693)
Balance (in Shares) at Jun. 30, 2025			133,014,673
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs (in shares)			355,871
Exercise of common stock options	192			192
Exercise of common stock options (in Shares)			77,226
Exercise of common warrants	184			184
Exercise of common warrants (in shares)			85,163
Issuance of shares for asset purchase agreement	20,394			20,394
Issuance of shares for asset purchase agreement (in shares)			1,194,820
Stock-based compensation expense	3,909			3,909
Net loss	483				483
Foreign currency translation adjustment	(65)					(65)
Balance at Sep. 30, 2025	$ (22,118)		$ 15	$ 958,216	$ (983,397)	$ 3,741	$ (693)
Balance (in Shares) at Sep. 30, 2025			134,727,753